Pembrolizumab works by blocking a mechanism that cancer cells use to evade detection by the immune system, according to Drugs.com. The U.S. Food and Drug Administration (FDA) first approved it in 2014 ...

Moderna and Merck's melanoma vaccine, combined with Keytruda, could halve cancer recurrence risk, marking a breakthrough in ...

In patients with high-risk melanoma, the personalized cancer vaccine intismeran autogene and Keytruda reduced the risk of ...

Patients with severe melanoma who received the treatment were 49% less likely to die or have their cancer return, ...

Placer County is holding a campaign for Cancer Prevention Day, focusing on education and a free skin cancer webinar.

A personalized cancer treatment developed by Moderna Inc. and Merck & Co. helped prevent the recurrence of high-risk skin ...

New research suggests that the timing of skin cancer prevention may be more important than previously assumed.

Researchers analyzed the health records of more than 33,800 U.S. veterans diagnosed with non-melanoma skin cancer and found ...

Neoadjuvant pembrolizumab achieved a 71% pCR rate in desmoplastic melanoma, surpassing expectations for neoadjuvant anti–PD-1 treatment. The 3-year relapse-free survival rate was 74%, and the overall ...

May is Skin Cancer Awareness Month, and we're focusing on melanoma, one of the most dangerous skin cancers. Join Piper Vaughn as she shares the ABCDE guide for early detection and essential sun safety ...